Abemaciclib for Ewing Sarcoma
This trial is testing whether adding abemaciclib to chemotherapy helps treat Ewing's sarcoma that has come back or did not respond to treatment. Participation could last 11 months or longer.
- Ewing Sarcoma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2018 Phase 2 trial • 132 Patients • NCT02102490
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is enrollment for this clinical research study open to the public?
"As seen on clinicaltrials.gov, recruitment is still in progress for this study which was initially posted to the database on September 20th 2022 and most recently updated November 22nd 2022."
What potential hazards could arise from using Abemaciclib?
"Abemaciclib received a score of 2 on our safety measure as it is currently in Phase 2. There are some studies supporting the drug's security, however no data has been collected to demonstrate its efficacy yet."
In how many healthcare centers is this clinical trial currently ongoing?
"This clinical trial is actively enrolling patients in Phoenix, Los Angeles and Indianapolis at relevant pediatric hospitals. Additionally, there are 5 other sites participating nationwide."
How many participants are being included in this research project?
"Eli Lilly and Company are responsible for the conduct of this trial, which requires 45 patients that meet their criteria. The study will be administered from two sites: Phoenix Children's Hospital in Arizona and The Regents of the University of California - Los Angeles (UCLA Pediatrics) at Los Angeles."
Are participants aged over 45 accepted for the trial?
"This trial only permits those between the age of one year and 39 years. Conversely, 194 studies are available for younger patients while 974 pertain to individuals aged 65 or older."
Is it possible for me to join this clinical experiment?
"Prospective participants must meet two criteria; they must have neoplasm metastasis and be between one year old to 39 years of age. The total number of enrollments is limited to 45 individuals."